Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin s Lymphoma
|
|
- Bathsheba Ryan
- 5 years ago
- Views:
Transcription
1 Biology of Blood and Marrow Transplantation 12: (2006) 2006 American Society for Blood and Marrow Transplantation /06/ $32.00/0 doi: /j.bbmt Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin s Lymphoma Roberto Rodriguez, 1 Auayporn Nademanee, 1 Nora Ruel, 1 Eileen Smith, 1 Amrita Krishnan, 1 Leslie Popplewell, 1 Jasmine Zain, 1 Kathy Patane, 1 Neil Kogut, 2 Ryotaro Nakamura, 1 Clarence Sarkodee-Adoo, 3 Stephen J. Forman 1 1 Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California; 2 Southern California Permanente Bone Marrow Transplant Program, Duarte, California; and 3 City of Hope Good Samaritan Transplant Program, Phoenix, Arizona Correspondence and reprint requests: Roberto Rodriguez, MD, Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, 1500 E Duarte Road, MOB 3001, Duarte, CA ( robertorodgriguez@coh.org). Received December 5, 2005; accepted August 20, 2006 ABSTRACT Reduced-intensity regimens (RIRs) are being used with increasing frequency in patients with non-hodgkin s lymphoma (NHL) undergoing allogeneic transplantation. The impact of dose reduction on relapse and survival has not been extensively studied. We performed a retrospective analysis of 88 patients conditioned with conventional myeloablative regimens (CMRs) (n 48) and an RIR (n 40) of fludarabine 125 mg/m 2 and melphalan 140 mg/m 2. Compared with the patients receiving CMR, those receiving RIR were older, had more often failed autologous transplantation, and had more frequently received peripheral blood and unrelated donor transplants. Graft-versus-host disease prophylaxis was provided with cyclosporine methotrexate prednisone for the CMR and with cyclosporine mycophenolate methotrexate for the RIR. The relapse rate was significantly lower in the patients receiving CMR than in those receiving RIR (13% vs 28%; P.05). The 1-year transplantation-related mortality rate was 33% for CMR and 28% for RIR (P.40). Kaplan-Meier 2-year overall survival and progression-free survival were 52% and 46% for CMR versus 53% and 40% for RIR (P not significant). Using cumulative incidence functions based on competing risks, univariate analysis, and treatment-related prognostic factors, we found that higher treatment intensity (P.03; relative risk [RR] 35%) and absence of previous autologous transplantation (P.0007; RR 20%) were associated with a lower relapse rate. Using a Cox univariate proportional hazards model, we found that chemosensitive disease at transplantation (P.05; RR 57%) and absence of previous autologous transplantation (P.002; RR 37%) were associated with improved survival. Our observation of similar survival in the patients receiving CMR and those receiving RIR confirms that RIRs are feasible alternatives for high-risk patients with NHL; however, the data suggest that reduced treatment intensity and previous autologous transplantation are associated with increased relapse American Society for Blood and Marrow Transplantation KEY WORDS Reduced-intensity conditioning regimen Allogeneic stem cell transplantation Non-Hodgkin s lymphoma Reduced-intensity regimens (RIRs) carry reduced regimen-related toxicity and mortality after allogeneic hematopoietic cell transplantation (HCT) for various hematologic malignancies, allowing older and sicker patients to undergo this procedure. By decreasing the cytoreductive properties of therapy, RIRs shift the burden of therapy toward the immunologic power of the graft (graft-versus-malignancy effect [GVM]). Thus, relapse may be more common in patients with malignancies less sensitive to the GVM effect, potentially offsetting any survival benefit. Few long-term reports have studied the outcome for non-hodgkin s lymphoma (NHL) after RIRs. Allogeneic HCT for NHL is usually recommended for patients with high-risk disease who are poor candidates for high-dose chemotherapy with au- 1326
2 Reduced-Intensity and Conventional Myeloablative Regimens 1327 tologous HCT or have relapsed after this procedure. Conventional myeloablative regimens (CMRs) are associated with prohibitive transplantation-related mortality (TRM) for patients failing autologous transplantation [1,2], and RIRs have reopened the possibility of exploring allogeneic transplantation in this setting. Early TRM for such patients has been acceptable [3,4], but the long-term benefit of this approach has not been well studied. At our institution, all patients with NHL undergoing allogeneic transplantation since the year 2000 were conditioned with an RIR. To determine whether this strategy had an impact on relapse and survival, we compared the cohort of patients receiving the RIR of fludarabine and melphalan (flu/mel) with our experience using CMR during the previous decade. Herein we report the results of this analysis on 88 consecutive patients who underwent transplantation since METHODS The City of Hope Lymphoma database was used to identify all patients with NHL undergoing allogeneic transplantation at our institution. Two cohorts of patients were retrospectively analyzed and compared for survival outcomes and risk of relapse. The first cohort included all patients who underwent allogeneic transplantation between 1991 and 2000, when fractionated total body irradiation (FTBI) was uniformly incorporated into our conditioning regimens; during this period, all patients were conditioned with a CMR. The second cohort included all patients conditioned with an RIR of flu/mel between 2000 and December The patients were further analyzed according to 4 diagnostic categories: intermediate grade B-cell (diffuse large B-cell, including transformed disease and follicular grade 3), low-grade B-cell (follicular grade 1 and 2, and chronic lymphocytic leukemia/small lymphocytic lymphoma), mantle cell, and T-cell. Patients with high-grade histologies according to the Working Formulation [5] were excluded because of the small number of these patients. This analysis was reviewed and approved by the City of Hope s institutional review board. Treatment Patients in the CMR group received an FTBIbased regimen (n 41) or busulfan and cyclophosphamide (n 7) if there were contraindications for FTBI. The dose of FTBI was 1320 cgy in 11 fractions. Cyclophosphamide was given after FTBI, at a dose of 60 mg/kg of ideal body weight. The flu/mel RIR comprised fludarabine 25 mg/m 2 daily for 5 days, followed by melphalan 140 mg/m 2 intravenously. Graft-versus-host disease (GVHD) prophylaxis in CMR comprised cyclosporine and methotrexate, with or without methylprednisolone. In contrast, GVHD prophylaxis in RIR comprised cyclosporine and mycophenolate mofetil for patients receiving matched sibling donor HCT, with the addition of methotrexate for those receiving unrelated donor HCT. Supportive Care Antimicrobial prophylaxis, blood product transfusions, growth factor support, and treatment of GVHD were given in accordance with institutional guidelines or protocols available at the time of transplantation. The stem cell source was determined by the treating physician or donor availability. Peripheral blood and bone marrow were procured from sibling donors or unrelated donors through the National Marrow Donor Program according to guidelines available at the time of collection. Assessment of Outcome Response and relapse were defined according to standard criteria for lymphoma [6]. Patients still alive at the time of analysis were censored at the last follow-up date. Overall survival (OS) was measured from the time of transplantation until death or the last follow-up. Progression-free survival (PFS) was measured from transplantation until progression or death from any cause. TRM was measured from the date of transplantation to the date of death from complications of transplantation. Statistical Methods Demographic and disease characteristics were summarized for all patients using descriptive statistics. The probabilities of OS and PFS were estimated using Table 1. Patient characteristics CMR RIR P Value N Low-grade B-cell NS Intermediate-grade B-cell NS Mantle-cell 10 5 NS T-cell 4 7 NS Age (years, median, range) 44 (18-54) 51 (20-67).0002 Previous regimens (median) Previous autologous transplantation Chemosensitivity at transplantation FTBI regimen 41 0 <.0001 MUD PBSCs Median follow-up (months, range) 69 (33-97) 20 (6-42) NS indicates not significant; MUD, matched unrelated donor; PBSCs, peripheral blood stem cells.
3 1328 R. Rodriguez et al. Table 2. Histological diagnoses Histology CMR (n 48) RIR (n 40) Intermediate-grade B cell DLCL 9 7 t-dlcl* 7 3 Follicular grade 3 2 Low-grade B cell Follicular grade 1/ SLL/CLL 8 8 Mantle cell 10 5 T cell 4 7 CTCL 4 4 AILD 1 PLL 1 ALCL 1 DLCL indicates diffuse large-cell lymphoma; SLL, small lymphocytic lymphoma; CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; AILD, angioimmunoblastic lymphadenopathy with dysproteinemia; PLL, prolymphocytic leukemia; ALCL, anaplastic large-cell lymphoma. *Transformed. the Kaplan-Meier method. Two-tailed tests of significance were used, with variables defined as significant if P values were at least.05. Survival estimates were calculated based on the product-limit method, and 95% confidence intervals were calculated using the logit transformation with Greenwood s variance estimate. TRM and relapse rates were analyzed using cumulative incidence functions based on competing risks. Cumulative incidence and P values were estimated using the cmprsk package of Gray [7] written in R version [8]. Unless otherwise indicated, Kaplan-Meier log-rank P values are reported for PFS and OS. Competing risk regression P values were estimated using cmprsk and the proportional hazards subdistribution model of Fine and Gray [9], whereas factors possibly associated with OS and PFS were examined by univariate Cox regression analysis [10]. The variables tested included age, treatment intensity, disease grade, remission status, number of previous regimens, sibling versus unrelated transplantation, chemosensitivity, and previous autologous transplantation. The risk ratio was calculated for each variable. The 2-sided Fisher s exact test was used to compare proportions. The assumption of proportionality of the hazard ratio was tested for each variable between the 2 groups [11]. The 2-sample t test was used to compare sample means and continuous variables. GVHD was reported using crude incidence rates. RESULTS Patient Characteristics A total of 88 patients with low-grade (n 34), intermediate grade (n 28), mantle cell (n 15), and T-cell (n 11) NHL underwent allogeneic HCT with CMR (n 48) or flu/mel RIR (n 40) (Table 1). Specific histologies are given in Table 2. Since the year 2000, patients were considered eligible for the flu/mel RIR if they had a diagnosis of NHL regardless of age, with creatinine clearance 40 ml/min, carbon monoxide diffusion capacity (DLCO) of 40% of predicted, and cardiac ejection fraction (EF) of 45%. High-risk features for TRM for this cohort included previous autologous transplan- Figure 1. Probability of relapse at 2 years for all patients based on conditioning treatment intensity: 28% for RIR and 13% for CMR (P.05).
4 Reduced-Intensity and Conventional Myeloablative Regimens 1329 Figure 2. OS and PFS based on conditioning treatment intensity. tation (n 15), age 50 years (n 23), DLCO 50 (n 1), and EF 50% (n 1). Significant differences were observed between the 2 groups. Compared with the patients receiving RIR, those receiving CMR were more likely to be younger, to have been more heavily pretreated, and to have more often received a matched sibling transplant and bone marrow as the transplant source. Conversely, the patients receiving RIR were more likely to have previously received an autologous transplant. As expected, follow-up was longer for the patients receiving CMR. Relapse, PFS, and OS Overall, 20 patients relapsed, 12 after RIR and 8 after CMR, for 2-year relapse rates of 28% and 13%, respectively (P.05), (Figure 1). When analyzed by diagnostic category, patients with intermediate-grade B-cell lymphoma had a statistically significant higher Figure 3. TRM based on conditioning treatment intensity.
5 1330 R. Rodriguez et al. 2-year relapse rate after RIR (44%) compared with CMR (12%) (P.02). The 2-year relapse rates for patients with low-grade disease were 19% after RIR and 12% after CMR (P.56), and those for patients with mantle cell disease were 60% after RIR and 20% after CMR (P.05). No relapses were observed in patients with T-cell disease in either cohort. OS and PFS were not statistically different between the patients receiving RIR and those receiving CMR. The 2-year OS was 53% for RIR and 52% for CMR (P.99), and the 2-year PFS was 40% for RIR and 46% for CMR (P.46) (Figure 2). Similarly, by diagnostic category, there were no statistically significant differences in OS or PFS. The 2-year OSs by diagnostic category after RIR and CMR, respectively, were 36% and 50% (P.32) for intermediate grade B-cell disease, 68% and 56% (P.56) for low-grade B-cell disease, 30% and 50% (P.6) for mantle cell disease, and 57% and 50% for T-cell disease. The 2-year PFSs after RIR and CMR, respectively, were 31% and 44% (P.18) for intermediate grade B-cell disease, 49% and 50% (P.83) for low grade B-cell disease, 20% and 40% (P.36) for mantle cell disease, and 57% and 50% for T-cell disease. TRM and Cause of Death The risk of 2-year TRM was 28% for RIR and 38% for CMR (P.4) (Figure 3). Analysis of risk factors for nonrelapse mortality, including age ( 50 years), donor type (related vs unrelated), diagnosis, chemosensitivity at time of transplantation, stem cell source, previous autologous transplantation, and type of conditioning regimen, showed a trend for previous autologous transplantation predicting for TRM (P.07). Among the patients receiving RIR, 18 patients have died, due to relapse (n 7), GVHD (n 8), infection without GVHD (n 2), or interstitial pneumonia (n 1). Of the patients conditioned with CMR, 27 have died; causes of death included relapse (n 6), GVHD (n 4), infection without GVHD (n 8), veno-occlusive disease of the liver (n 2), interstitial pneumonitis/diffuse alveolar hemorrhage (n 2), graft failure (n 1), encephalitis (n 1), renal failure (n 1), and unknown (n 2). GVHD Incidence of grade II IV acute GVHD was 45% after CMR and 65% after RIR. Incidence of chronic GVHD was 72% (37% extensive) and 76% (50% extensive) of evaluable patients after CMR and RIR, respectively. Univariate Analysis Univariate analysis identified the following variables as significantly associated with improved OS: chemosensitive disease at time of transplantation (P.05; relative risk [RR] 57%) and absence of previous autologous transplantation (P.002; RR 37%). Similarly, PFS was higher for patients with chemosensitive disease (P.04; RR 57%) (Table 3). Significant predictors of relapse included treatment intensity and previous autologous HCT. Both CMR (P.05; RR 35%) and absence of previous autologous HCT (P.0007; RR 20%) significantly reduced the incidence of relapse. The data at hand suggest that previous autologous transplantation had a dominant effect on relapse and survival. The relative contributions of previous autologous transplantation and dose intensity on relapse and survival by multivariate analysis cannot be reliably estimated because of limited observations in these strata, with only 5 CMR patients receiving previous autologous transplantation. Within the RIR cohort Table 3. Results of Univariate Analysis OS PFS Relapse Rate P Value P Value P Value Conditioning treatment intensity RIR Default Default Default CMR RR 35% Diagnosis/histology Low-grade Intermediate-grade Mantle-cell lymphoma Age (continuous) Remission status (disease status at transplantation) Not in remission Default Default Default In remission Number of previous regimens 1 or 2 regimens or more regimens Default Default Default FTBI No Default Default Default Yes Donor type Matched unrelated donor Default Default Default Sibling Chemosensitivity Resistant relapse Default Default Default Sensitive relapse rr 57% rr 57% Previous autologous transplantation Yes Default Default Default No rr 37% rr 32% rr 20% OS and PFS univariate proportional hazards P values are based on Cox models; relapse rates are based on competing-risks regression.
6 Reduced-Intensity and Conventional Myeloablative Regimens 1331 Figure 4. OS and PFS for patients receiving RIR, based on previous autologous transplantation. alone, patients who failed a previous autologous transplantation (n 15) were at higher risk of relapse (P.03) and had significantly worse PFS (P.02) and OS (P.06) (Figures 4 and 5). DISCUSSION The premise behind RIRs to reduce TRM while preserving the antitumor effect of the graft is one of the major recent advances in HCT [12]. Although this less toxic approach is likely to improve survival for patients with malignancies sensitive to the GVM effect, others may suffer higher relapse rates, ultimately defeating the curative purpose of the transplantation. Studies have found that reducing the intensity of the conditioning regimen is associated with increased relapse for chronic myeloid leukemia and acute myeloid leukemia in the settings of CMR [13,14] and RIR [15]. This retrospective comparison of the 2 conditioning treatments for NHL showed no significant differ- Figure 5. Probability of relapse for patients receiving RIR based on previous autologous transplantation.
7 1332 R. Rodriguez et al. ence in survival despite a lower relapse with CMR. Given that TRM was similar in the 2 cohorts, we speculate that longer follow-up of the RIR cohort likely will lead to a survival difference favoring CMR. These observations must be interpreted within the context of different patient characteristics between cohorts, such that the RIR group was at higher risk of TRM because of greater age, previous autologous transplantation, and unrelated donor source. Thus, RIR allowed older and sicker patients to receive potentially curative transplants without significantly increasing TRM. Severe GVHD rates were higher in the RIR group. This paradoxical observation may be explained by a higher proportion of older patients and unrelated donor transplants in this cohort; in addition, prophylaxis with cyclosporine and mycophenolate mofetil, which has been associated with acceptable rates of acute GVHD in the nonmyeloablative setting [16], may not be adequate with the flu/mel RIR [17]. Recently, 2 studies using RIR for NHL suggested high relapse rates after RIR for aggressive histology and refractory disease [18,19] with results similar to ours. In the first series, 88 patients with relapsed and refractory NHL (33 diffuse large-cell lymphoma [DLCL] or transformed disease, 41 low-grade lymphoma, and 10 mantle-cell lymphoma) conditioned with an RIR of alemtuzumab, fludarabine 150 mg/m 2, and melphalan 140 mg/m 2, had actuarial 3-year OS, PFS, and relapse rates of 34%, 34%, and 52%, respectively, in the aggressive lymphomas; 60%, 50%, and 50% in mantle-cell lymphoma; and 73%, 65%, and 44% in low-grade NHL [18]. The second report of 188 patients with NHL reported to the European Group for Blood and Marrow Transplantation (62 aggressive histology; 52 low-grade and 22 mantle cell) treated with various RIRs, showed 1-year PFS and probability of relapse of 32% and 47%, respectively, for aggressive histology; 61% and 21% for low-grade disease; and 31% and 48% for mantle-cell disease [19]. These findings support a role for intensifying the regimen for intermediate-grade B-cell and mantle-cell NHL. A recent study by the Seattle Consortium (including City of Hope), using a nonmyeloablative regimen of fludarabine and 2 Gy total body irradiation (TBI) for aggressive NHL, found that among 40 patients with aggressive NHL (31 with DLCL), the 1 year OS, PFS, and relapse rates were 63%, 49%, and 36%, respectively [20]. Chemosensitive disease was present in 28 patients at time of transplantation and appeared to be predictive of outcome. These favorable results may reflect differences in patient characteristics, such as proportion of transformed and chemosensitive disease at time of transplantation. Interestingly, we found that absence of previous autologous transplantation strongly predicted for improved OS (P.02, hazard ratio [HR] 0.37) and decreased relapse (P.0007; HR 0.2), with a trend toward lower TRM (P.07). Thus, RIR offers the possibility of allogeneic transplantation for these patients, but outcome is offset by higher relapse and TRM. These results suggest that high-dose chemotherapy may lead to greater chemoresistance and organ toxicity, potentially offsetting any graft-versus- Figure 6. OS based on chemosensitivity (SR, sensitive relapse; RR, refractory relapse).
8 Reduced-Intensity and Conventional Myeloablative Regimens 1333 leukemia (GVL) effect. Because previous autologous transplantation co-segregated closely with reduced treatment intensity in this study, we could not determine the strength of each variable as a prognostic factor; within the RIR cohort, failing a previous autologous transplantation had a significant negative impact on relapse and survival (Figures 4 and 5). As with other series, our experience shows that chemosensitivity at the time of transplantation is associated with better survival (Figure 6) [18,21]. Our results should be interpreted with caution given the retrospective nature of the analysis, the different patient characteristics between cohorts, and the small number of patients within each category of lymphoma. We grouped patients into diagnostic categories reflecting clinical behavior and cell of origin; considering the biologic heterogeneity of lymphomas, however, the sensitivity to the GVL effect may vary within those relatively homogenous categories (eg, de novo DLCL vs transformed lymphoma, follicular lymphoma vs chronic lymphocytic leukemia, and cutaneous T-cell lymphoma vs other T-cell lymphomas). Moreover, genetic differences within specific histologies [22] likely will influence responses to allografting, and such testing may enhance the understanding of the immune processes involved in the GVL effect and yield useful predictive information before transplantation. In our patient population, survival was similar between the patients receiving CMR and those receiving RIR, confirming that RIR is safe for older and sicker patients. However, treatment intensification appeared to be important for disease control in some patients, particularly those with DLCL, B-cell, and mantle-cell lymphoma. Patients failing previous autologous transplantation and with chemorefractory disease were at high risk of relapse and death. Newer approaches to improving the cytoreductive properties of the regimen while preserving a low TRM, such as substituting TBI with radio-immunoconjugates and increasing responses before transplantation, will be needed to improve survival in these patients. REFERENCES 1. Ringden O, Labopin M, Frassoni F, et al. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;24: Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20: Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89: Porter DL, Luger SM, Duffy KM, et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001;7: National Cancer Institute sponsored study of classifications of non-hodgkin s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin s Lymphoma Pathologic Classification Project. Cancer. 1982;49: Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non- Hodgkin s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17: Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16: R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: Mehta CR, Patel NR. A network algorithm for performing Fisher s exact test in rxc contingency tables. J Am Stat Assoc. 1983;78: Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol. 1999;11: Clift RA, Radich J, Appelbaum FR, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during the chronic phase of chronic myeloid leukemia. Blood. 1999;94: Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997; 89: de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104: Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101: Rodriguez R, Parker P, Nademanee A, et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant. 2004;33: Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-hodgkin s lymphoma. Blood. 2004;104:
9 1334 R. Rodriguez et al. 19. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100: Norasetthada L, Maris MB, Sandmaier BM, et al. HLAmatched related (MRD) or unrelated (URD) non-myeloablative hematopoietic cell transplantation (HCT) for patients with refractory and relapsed aggressive non-hodgkin s lymphoma [abstract]. Blood. 2004;104:634a. 21. Dean RM, Fowler DH, Wilson WH, et al. Efficacy of reducedintensity allogeneic stem cell transplantation in chemotherapyrefractory non-hodgkin s lymphoma. Biol Blood Marrow Transplant. 2005;11: Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:
Reduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationKEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationNon-Myeloablative Transplantation
Non-Myeloablative Transplantation David G. Maloney, Brenda M. Sandmaier, Stephen Mackinnon, and Judith A. Shizuru The concept of utilizing enhanced immunosuppression rather than myeloablative cytotoxic
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationHigh-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 12:703-711 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0002$32.00/0 doi:10.1016/j.bbmt.2006.02.009 High-Dose Carmustine,
More informationReduced-Intensity Allogeneic Bone Marrow Transplantation
Reduced-Intensity Allogeneic Bone Marrow Transplantation Session Chair: Claudio Anasetti, MD Speakers: Brenda M. Sandmaier, MD; Issa F. Khouri, MD; and Franco Locatelli, MD Outcomes with Myeloid Malignancies
More informationDose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation
(2005) 19, 171 175 & 2005 Nature Publishing Group All rights reserved 0887-6924/05 $30.00 www.nature.com/leu KEYNOTE ADDRESS Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell
More informationEffect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation Authors: Hirohisa Nakamae, 1 Katharine A. Kirby, 1 Brenda M. Sandmaier, 1,2
More information& 2005 Nature Publishing Group All rights reserved /05 $
(2005) 35, 943 951 & 2005 Nature Publishing Group All rights reserved 0268-3369/05 $30 www.nature.com/bmt Conditioning regimens Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory
More informationOptimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS)
Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) H. Joachim Deeg Myelodysplastic syndrome (MDS) is a hemopoietic stem cell disorder that is potentially curable by transplantation
More informationImproving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma using Radioimmunotherapy
Biology of Blood and Marrow Transplantation 12:697-702 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0001$32.00/0 doi:10.1016/j.bbmt.2006.03.014 Improving the Efficacy
More informationFeasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
The Open Leukemia Journal, 2010, 3, 55-59 55 Open Access Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than Years
More informationKEY WORDS Leukemia Myelodysplastic syndrome Transplant Aging
Biology of Blood and Marrow Transplantation 13:454-462 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1304-0001$32.00/0 doi:10.1016/j.bbmt.2006.11.024 Allogeneic Hematopoietic
More informationKEY WORDS: Nonmyeloablative, Umbilical cord blood, Lymphoid malignancies
Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation Claudio G. Brunstein, 1,2 Susana Cantero, 1
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationBB&MT. KEY WORDS Reduced-intensity regimen Allogeneic hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation 9:189 197 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0903-0007$30.00/0 doi: 10.1053/bbmt.2003.50012 Lowered-Intensity Preparative
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationReduced intensity conditioning regimens
Reduced intensity conditioning regimens (2002) 30, 63 68 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Low transplant-related mortality after second allogeneic
More informationHematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0004$32.00/0 doi:10.1016/j.bbmt.2005.06.004 High Disease Burden
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationReduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink
Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink Avichi Shimoni, Arnon Nagler Hematology Division and BMT, Chaim Sheba Medical Center,
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationClinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin s Lymphoma
Biology of Blood and Marrow Transplantation 12:965-972 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1209-0001$32.00/0 doi:10.1016/j.bbmt.2006.05.018 Clinical Outcome following
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More informationHLA-Matched Unrelated Donor Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Chronic Myeloid Leukemia
Biology of Blood and Marrow Transplantation 11:272-279 (2005) 2005 American Society for Blood and Marrow Transplantation 1083-8791/05/1104-0005$30.00/0 doi:10.1016/j.bbmt.2004.12.326 HLA-Matched Unrelated
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationMedical Benefit Effective Date: 07/01/12 Next Review Date: 05/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 05/11, 05/12
Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic (80115) Medical Benefit Effective Date: 07/01/12 Next Review Date: 05/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 05/11, 05/12 The
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationLow T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC
(23) 32, 829 834 & 23 Nature Publishing Group All rights reserved 268-3369/3 $25. www.nature.com/bmt Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation
More informationBusulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate
Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationGraft-versus-Host Disease, Donor Chimerism, and Organ Toxicity in Stem Cell Transplantation after Conditioning with Fludarabine and Melphalan
Biology of Blood and Marrow Transplantation 9:435-442 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0907-0003$30.00/0 doi:10.1016/s1083-8791(03)00128-9 Graft-versus-Host
More informationRIC in Allogeneic Stem Cell Transplantation
RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants
More informationClinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes
Advances in Hematology Volume 2011, Article ID 601953, 8 pages doi:10.1155/2011/601953 Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes Jason R. Westin, 1 Rima M. Saliba, 1 Marcos
More informationOutline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT
Comorbidities before Allogeneic Hematopoietic Cell Transplantation (HCT) The HCT-specific Comorbidity Index (HCT-CI) Mohamed Sorror, M.D., M.Sc. FHCRC Seattle, WA Outline Pretransplant Essential data Why
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationNonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism
Nonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism THOMAS R. SPITZER Bone Marrow Transplant Program, Harvard Medical School, Boston, Massachusetts, USA Key Words.
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationMini-review Stem cell transplantation (SCT) for Waldenstrom s macroglobulinemia (WM)
(2002) 29, 943 947 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Mini-review Stem cell transplantation (SCT) for Waldenstrom s macroglobulinemia (WM) Department
More informationKEY WORDS: Total body irradiation, acute myelogenous leukemia, relapse
The Addition of 400 cgy Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationKEY WORDS: Comorbidity index, Reduced-intensity conditioning stem cell transplantation, Allo-RIC, HCT-CI, Mortality INTRODUCTION
Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor
More information2/4/14. Disclosure. Learning Objective
Utilizing Intravenous Busulfan Pharmacokinetics for Dosing Busulfan And Fludarabine Conditioning Regimens In Institutions Where The Capability Of Doing Pharmacokinetics Is Not Present Shaily Arora, PharmD
More informationEffect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, 1,2 John E. Wagner, 1,3 Todd E. DeFor, 1 Daniel J. Weisdorf, 1,2 Claudio
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplant for Non-Hodgkin Lymphomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_non_hodgkin_lymphomas
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationNon-Myeloablative Transplants for Malignant Disease
Non-Myeloablative Transplants for Malignant Disease Rainer F. Storb, Richard Champlin, Stanley R. Riddell, Makato Murata, Sophia Bryant, and Edus H. Warren This article discusses changes in the way hematopoietic
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationIntensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Bone Marrow Transplantation, (1998) 22, 1029 1033 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 http://www.stockton-press.co.uk/bmt Intensified conditioning regimen in bone marrow transplantation
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationBMT CLINICAL TRIALS NETWORK RIC vs. MAC Protocol # 0901 Version 5.0 dated March 3, 2014
Core Study Participants: Baylor College of Medicine (Methodist ) BMT at Northside Hospital Case Western Reserve University Consortia Cleveland Clinic Foundation Oregon Health and Science University University
More informationAllogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission Je-Hwan Lee 1, Sung-Soo
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (2013) 661e675 Brief Articles Improved Survival over the Last Decade in Pediatric Patients Requiring Dialysis after Hematopoietic Cell Transplantation American Society for
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationNonmyeloablative Allogeneic Transplants of Hematopoietic Stem Cells for Treatment of Malignancy Archived Medical Policy
Nonmyeloablative Allogeneic Transplants of Hematopoietic Stem Cells for Treatment of Malignancy Codes associated with this policy will no longer pend for clinical review. Applies to all products administered
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationLow-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin Conditioning for Nonmyeloablative Allogeneic Transplantation
Biology of Blood and Marrow Transplantation 9:453-459 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0907-0005$30.00/0 doi:10.1016/s1083-8791(03)00139-3 Low-Dose Total Body
More informationORIGINAL ARTICLE INTRODUCTION THE KOREAN JOURNAL OF HEMATOLOGY
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic
More informationJ Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 2 JANUARY 10 2009 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the Eurocord Office, Hôpital Saint Louis; Hôtel Dieu, Nantes; Hôtel Dieu, Paris; Hôpital La Miletrie, Poitiers;
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationVC 2007 Wiley-Liss, Inc.
Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis Catherine M. Flynn, 1,3 Betsy Hirsch,
More informationDonor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma
(2002) 29, 65 620 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Donor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation
More informationNonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism Thomas R. Spitzer. doi: /theoncologist.
Nonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism Thomas R. Spitzer The Oncologist 2000, 5:215-223. doi: 10.1634/theoncologist.5-3-215 The online version of this
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationLondon, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION
London, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION 1 Introduction Busilvex contains the active substance busulfan in a concentrate for solution for
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (213) 1381e1386 Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation American Society
More informationBACKGROUND AND RATIONALE
SYNOPSIS Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of
More informationReduced intensity conditioning for allogeneic haematopoietic stem cell transplantation (HSCT)
1 Reduced intensity conditioning for allogeneic haematopoietic stem cell transplantation (HSCT) S. Servais, Y. Beguin, F. Baron Reduced intensity conditioning (RIC) regimens have allowed performing allogeneic
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationClinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias
Go Clinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias Number: 0640 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Additional Information
More informationTrapianto allogenico
POST ASH 2013: 3 Workshop Regionale Marchigiano 28 Febbraio - 1 Marzo 2014 Hotel Domus Stella Maris, ANCONA REPORT OF THE BEST ASH NEWS Trapianto allogenico Dr. Claudio Giardini U.O. Ematologia e Centro
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More information